Regeneron Pharmaceuticals, Inc.
HIGH CONCENTRATION ANTI-C5 FORMULATIONS
Last updated:
Abstract:
The present disclosure includes high concentration, low viscosity pharmaceutical formulations that include an anti-C5 antibody or antigen-binding fragment thereof and arginine. Such formulations may be provided in association with an RNAi molecule such as cemdisiran. Methods of treating C5-associated diseases such as PNH and aHUS are also provided.
Status:
Application
Type:
Utility
Filling date:
14 Aug 2020
Issue date:
18 Feb 2021